



August 31, 2021

Web Announcement 2574

Drug Use Review (DUR) Board Approves Changes Effective September 1, 2021

The Nevada Medicaid Drug Use Review (DUR) Board met on April 22, 2021, and voted to adopt the following changes effective September 1, 2021:

Drug Class/Program	Changes
Multiple Sclerosis (MS) Agents	Added new prior authorization criteria for Kesimpta®.
Hereditary Angioedema Agents	Updated prior authorization criteria.
Narcolepsy Agents	Added new prior authorization criteria for Xywav™.
Hepatitis Agents	Daklinza®, Olysio®, Technivie® and Viekira XR® removed. Prior authorization criteria for Mavyret® updated length of approval to 8 weeks.
Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitor Agents	Added new prior authorization criteria for Nurtec® ODT.
Anticonvulsants	Updated prior authorization criteria for Valtoco® to remove requirement of diazepam rectal use for approval.

Prior authorization forms may be found on the Pharmacy Forms webpage at:

<https://www.medicaid.nv.gov/providers/rx/rxforms.aspx>